Clinical trial
Multiple Doses of AT-1501-A201 in Adults With ALS
NCT04322149
Study timeline
Study start (actual)2020-10-16Date precision: day
Registry last updated2023-06-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Amyotrophic Lateral Sclerosisunresolved
Interventions
AT-1501DRUG
Sponsors & collaborators
Anelixis Therapeutics, LLClead sponsor
Mapped research locations
New YorkNew York, United States1HoustonTexas, United States1BostonMassachusetts, United States1DallasTexas, United States1BaltimoreMaryland, United States1San FranciscoCalifornia, United States1PortlandOregon, United States1IndianapolisIndiana, United States1PhoenixArizona, United States1OrangeCalifornia, United States1Kansas CityKansas, United States1AugustaGeorgia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04322149 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.